Transcode Therapeutics, Inc. (RNAZ): Nasdaq/NYSE listing notice — TransCode receives Nasdaq delisting notice for minimum bid price and equity non-compliance; intends to appeal

Transcode Therapeutics, Inc.

Received delisting notice on May 7, 2024 for failing to regain compliance with $1.00 minimum bid price rule by May 6 deadline.
Not eligible for second 180-day compliance period due to failure to meet $5M minimum stockholders' equity requirement.
Company will request a hearing before Nasdaq Hearings Panel by May 14, 2024; hearing stays delisting pending outcome.
No assurance of regaining compliance; stock remains listed at least through the hearing process.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Transcode Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5505(b)(1), 5505(b)(2), 5505(b)(3)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5505(b)(1), 5505(b)(2), 5505(b)(3)

Exact text from the filing

May 7, 2024, (the “Notice”). The Notice was received from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that the Staff had determined that the Company has not regained compliance with the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule") and therefore the Company's common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff's delisting determination by requesting a hearing before the Panel. The Company's request for a hearing will stay any further delisting action by the Staff p

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-059963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.